Hexarelin vs GHRP-2: The Most Potent Growth Hormone Secretagogues Compared
Hexarelin and GHRP-2 are the two most potent GHSPs in terms of GH pulse amplitude, but hexarelin requires cycling due to faster receptor desensitization, and has unique cardiac research applications independent of GH. This comparison reviews the evidence.
Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) and GHRP-2 are the two most potent GH-releasing peptides characterised to date, with the highest GHS-R1a binding affinities among synthetic GHRPs. Both produce the largest acute GH pulses but carry significant secondary hormonal effects and differ critically in tachyphylaxis (receptor desensitisation over time).
Potency: Hexarelin's Edge
Hexarelin has GHS-R1a Ki approximately 3-5× lower (higher affinity) than GHRP-2. In Arvat E et al. (*JCEM*, 2000), hexarelin at 2 mcg/kg IV in healthy adults:
- Peak GH: 71.3 ± 12.2 ng/mL vs 52.6 ng/mL for GHRP-2 at equivalent dose
- ACTH: 3.1-fold elevation; Cortisol: 2.2-fold; Prolactin: 2.0-fold
Tachyphylaxis: Hexarelin's Major Limitation
Hexarelin's primary disadvantage is rapid receptor desensitisation. In subjects receiving hexarelin twice daily for 16 weeks, peak GH response declined to approximately 25% of initial response by week 8 (Ghigo E et al., 1999). GHRP-2 and Ipamorelin show far less tachyphylaxis.
The mechanism: hexarelin's very high affinity drives prolonged GHS-R1a occupancy and receptor clustering → internalisation → downregulation. Lower-affinity agonists dissociate more quickly, allowing receptor recycling.
Cardiac-Direct GHS-R1a Signalling
Hexarelin has documented cardiac protection in animal MI models that persists in hypophysectomised (pituitary-removed) rats — demonstrating direct cardiac GHS-R1a signalling independent of GH release. This mechanism reduces infarct size by ~30-40% and suggests a GH-independent cardioprotective pathway.
GHRP-2 has published cardiac protection that may involve both GH-dependent and GH-independent components, but the GH-independent cardiac GHS-R1a mechanism is less clearly established than for hexarelin.
Research Selection
- Single-dose GH amplitude studies: Hexarelin preferred (highest potency)
- Sustained protocols (weeks-months): Ipamorelin strongly preferred (no tachyphylaxis)
- High potency with moderate tachyphylaxis: GHRP-2 as middle ground
- Cardiac GH-independent research: Hexarelin preferred
Hexarelin and GHRP-2 are research peptides not approved for human therapeutic use.
About the Author
KnowYourPeptide Research Team
KnowYourPeptide Research Team
Content produced by the KnowYourPeptide research and editorial team. All articles are written from peer-reviewed primary literature and reviewed for scientific accuracy by credentialed researchers and a board-certified physician before publication.
Meet the full editorial teamMedically Reviewed by Dr. Amanda Reid, MD
This article has been reviewed by Dr. Amanda Reid, MD (Board-Certified Internal Medicine), Know Your Peptide Medical Advisor, for scientific accuracy, safety information, and appropriate clinical context. Learn about our review process.